Clinical Trial Detail

NCT ID NCT03601819
Title Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors University of Michigan Rogel Cancer Center
Indications

peripheral T-cell lymphoma

cutaneous T cell lymphoma

splenic marginal zone lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

chronic lymphocytic leukemia

Therapies

Pacritinib

Age Groups: adult senior

Additional content available in CKB BOOST